NVUS

Novus Therapeutics Stock Price

0.49
0.0169 (3.57%)
Upgrade to Real-Time
Regular Market
0.49
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Novus Therapeutics Inc NVUS NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
0.0169 3.57% 0.49 0.4713 0.49 0.4731 0.4731 09:44:52
Bid Price Ask Price Spread Spread % News
0.4715 0.49 0.0185 3.78% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
51 20,108 $ 0.4748069 $ 9,547 729,340 0.25 - 1.45
Last Trade Time Type Quantity Stock Price Currency
09:44:52 4,784 $ 0.49 USD

Novus Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.87M 16.07M 12.62M $ - $ - -1.41 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Novus Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVUS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.48430.500.43010.4669181234,0140.00571.18%
1 Month0.4950.640.420.5084729710,253-0.005-1.01%
3 Months1.061.450.420.66412911,197,172-0.57-53.77%
6 Months0.511.450.250.6513871704,030-0.02-3.92%
1 Year0.751.450.250.6479253415,986-0.26-34.67%
3 Years4.148.610.251.31187,750-3.65-88.16%
5 Years12.9114.21990.251.87274,265-12.42-96.2%

Novus Therapeutics Description

Novus Therapeutics Inc is engaged in the biotechnology sector. As a pharmaceutical company, it is focused on the acquisition, development, and commercialization of ear, nose, and throat related products. It has two platforms: Foam Platform(OP0201 and OP0202) and Surfactant Program(OP0201). OP0102 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP0201 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.